New 'Living Drug' trial targets tough blood cancers after other treatments fail
NCT ID NCT03960840
Summary
This study is testing a new type of personalized immune cell therapy called rapcabtagene autoleucel (a CAR-T cell therapy) for adults with several aggressive or returning blood cancers. The main goals are to find a safe and effective dose and to see if the therapy can shrink or eliminate tumors in patients who have few other options. It is for adults with specific types of leukemia and lymphoma that have not responded well to standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Mass Gen Hosp Cancer Center
Boston, Massachusetts, 02114, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Novartis Investigative Site
Melbourne, Victoria, 3000, Australia
-
Novartis Investigative Site
Melbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
Vienna, 1090, Austria
-
Novartis Investigative Site
Marseille, 13273, France
-
Novartis Investigative Site
Paris, 75475, France
-
Novartis Investigative Site
Pierre-Bénite, 69495, France
-
Novartis Investigative Site
Rennes, 35033, France
-
Novartis Investigative Site
Frankfurt am Main, Hesse, 60590, Germany
-
Novartis Investigative Site
Leipzig, Saxony, 04103, Germany
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Bergamo, BG, 24127, Italy
-
Novartis Investigative Site
Bologna, BO, 40138, Italy
-
Novartis Investigative Site
Milan, MI, 20132, Italy
-
Novartis Investigative Site
Rozzano, MI, 20089, Italy
-
Novartis Investigative Site
Sapporo, Hokkaido, 060 8648, Japan
-
Novartis Investigative Site
Bunkyo Ku, Tokyo, 1138677, Japan
-
Novartis Investigative Site
Fukuoka, 8128582, Japan
-
Novartis Investigative Site
Badalona, Barcelona, 08916, Spain
-
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Barcelona, 08041, Spain
-
Novartis Investigative Site
Córdoba, 14004, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Madrid, 28041, Spain
-
Novartis Investigative Site
Salamanca, 37007, Spain
-
Novartis Investigative Site
Seville, 41013, Spain
-
Novartis Investigative Site
Valencia, 46010, Spain
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37221, United States
-
St Davids South Austin Medical Ctr
Austin, Texas, 78704, United States
-
Stanford University Medical Center
Stanford, California, 94305-5826, United States
-
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas, 77030, United States
-
Uni of Chi Medi Ctr Hema and Onco
Chicago, Illinois, 60637, United States
-
University of California LA
Los Angeles, California, 90095, United States
-
University of Kansas Cancer Center
Westwood, Kansas, 66205, United States
-
University of Pennsylvania Clinical
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.